All In Biotech

NDA 008697 · Pharmacia and Upjohn

Cortef

Hydrocortisone · Oral · Corticosteroid

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1952

Dec 15, 1952

Approved uses

1

Original approval plus efficacy supplements

Registered trials

753

149 Phase 3, 82 recruiting

FAERS reports

70,802

58,283 serious, 10,246 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 25, 2026.

INDICATIONS AND USAGE Hydrocortisone tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster...

Mechanism: ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 15, 1952 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • CORTEF · HYDROCORTISONE 20MG · TABLET, ORAL · Prescription · TE AB
  • CORTEF · HYDROCORTISONE 5MG · TABLET, ORAL · Prescription · TE AB
  • CORTEF · HYDROCORTISONE 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 753 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use9,850
  • drug ineffective7,835
  • fatigue6,470
  • condition aggravated5,622
  • nausea5,378
  • rash5,086
  • headache4,757
  • diarrhoea4,750
  • pain4,696
  • dyspnoea4,614
  • arthralgia4,551
  • pyrexia4,192

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004493
2005606
2006574
2007610
2008646
2009793
2010913
20111,161
20121,881
20131,620
20141,888
20152,562
20163,006
20173,527
20185,022
20194,494
20205,500
20215,659
20226,276
20236,249
20246,572
20256,336
20264,410

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cortef (Hydrocortisone)

2024 spending

$612K

Beneficiaries

622

2,648 claims

Per beneficiary

$984

$1.30 per unit

View as table
YearSpending
2020$849,898
2021$729,899
2022$662,981
2023$682,964
2024$611,885

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,632 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.